{"disease":{"id":"thymic-neuroendocrine-carcinoma","name":"thymic neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06121271","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":110,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06141369","title":"Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)","phase":"NA","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}